Tilray (NASDAQ:TLRY) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Tilray (NASDAQ:TLRY) released its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.07), Zacks reports. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The business had revenue of $210.90 million for the quarter, compared to the consensus estimate of $216.34 million. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. Tilray updated its FY 2025 guidance to EPS.

Tilray Stock Down 9.1 %

Shares of TLRY traded down $0.13 during trading hours on Friday, hitting $1.25. The company had a trading volume of 27,340,392 shares, compared to its average volume of 45,380,848. Tilray has a one year low of $1.14 and a one year high of $2.97. The company’s fifty day moving average price is $1.37 and its two-hundred day moving average price is $1.62. The company has a market capitalization of $1.12 billion, a PE ratio of -4.61 and a beta of 2.08. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08.

Insider Activity at Tilray

In other Tilray news, CFO Carl A. Merton bought 26,000 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were purchased at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the purchase, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.87% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Roth Mkm lowered their price objective on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research note on Friday, October 11th.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.